FLECAINIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H20F6N2O3
Molecular Weight	414.3427
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(=C1)C(=O)NCC2CCCCN2

InChI

InChIKey=DJBNUMBKLMJRSA-UHFFFAOYSA-N

InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

HIDE SMILES / InChI

Molecular Formula	C17H20F6N2O3
Molecular Weight	414.3427
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB01195
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/flecainide.html

Flecainide is a potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Flecainide is sold under the trade name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent on February 10, 2004. In addition to being marketed as Tambocor, it is also available in generic version and under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Sodium channel protein type V alpha subunit 49 Target ID: CHEMBL1980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21194571	Inhibitor 8504	67.2 µM [IC50]
Sodium channel protein type IV alpha subunit 23 Target ID: CHEMBL2072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20590641	Inhibitor 8504	18.0 µM [Ki]
HERG 99 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26159617	Inhibitor 8504	1.49 µM [IC50]
Voltage-gated potassium channel subunit Kv4.3 7 Target ID: CHEMBL1964 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12875427	Inhibitor 8504	7.8 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Paroxysmal atrial fibrillation 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 8583	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 2001
Documented ventricular arrhythmias 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 8583	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 2001

C_max

Value	Dose	Co-administered	Analyte	Population
1710 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
355 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
5.9 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6238 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5979 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
60% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6364769			FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	Disc. AE: Unconsciousness, Cyanosis... AEs leading to discontinuation/dose reduction: Unconsciousness Cyanosis Bradycardia Arrhythmia Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 Health Status: healthy Age Group: 28 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	Disc. AE: Polymorphic ventricular tachycardia... AEs leading to discontinuation/dose reduction: Polymorphic ventricular tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	Disc. AE: Ventricular tachycardia, Hypotension... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Hypotension Cardiopulmonary arrest Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	Disc. AE: Brugada syndrome, Mental status changes... AEs leading to discontinuation/dose reduction: Brugada syndrome Mental status changes Fatigue Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	Disc. AE: Ventricular tachycardia, Cardiac arrest... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Cardiac arrest Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

AEs

AE	Significance	Dose	Population
Arrhythmia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Bradycardia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Cyanosis	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Unconsciousness	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156	healthy, 18 Health Status: healthy Age Group: 18 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20562156
Polymorphic ventricular tachycardia	Disc. AE	3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 Health Status: healthy Age Group: 28 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
Cardiopulmonary arrest	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
Hypotension	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
Ventricular tachycardia	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278	healthy, 36 Health Status: healthy Age Group: 36 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9825278
Brugada syndrome	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
Fatigue	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
Mental status changes	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://pubmed.ncbi.nlm.nih.gov/27884575	unhealthy, 62 Health Status: unhealthy Age Group: 62 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/27884575
Cardiac arrest	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
Ventricular tachycardia	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 779	CYP1A2 1197

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.44 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.49 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 191 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes
CYP2D6 1388	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes		yes (co-administration study) Comment: During the period in which the CYP2D6 inhibitor paroxetine was administered, the flecainide AUC in extensive and intermediate metabolizers was increased to 128.5% of basal values (90% CI, 122.2%– 135.2%) and 116.6% of basal values (90% CI, 107.3%–126.8%). However, poor metabolizers exhibited no alterations in AUC after administration of paroxetine (pharmacogenomic studies were also performed) Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573407/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:75984	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75984
ChemicalBook	CB0663265	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0663265
eMolecules	901891	https://www.emolecules.com/cgi-bin/more?vid=901891
MolPort	MolPort-003-847-380	https://www.molport.com/shop/molecule-link/MolPort-003-847-380

PubMed

Title	Date	PubMed
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.	2013-12	24052561
The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.	2013-03	23261645
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.	2012-10	22700542
Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.	2011-10	21515356
Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.	2011-09	21693436
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.	2011-07-10	21743453
Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.	2011-06	21641380
Iatrogenic Flecainide toxicity.	2010-12	20736205
Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.	2010-03-10	20219811
Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype.	2010-02	19897501
A case of flecainide-induced hyponatremia.	2009-10	19298558
Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.	2009-07	19531695
Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current.	2009-06	19498275
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.	2009-04	19174378
Is flecainide dangerous in long QT-3 patients?	2009-01	19140927
ECGs in the ED.	2008-11	19018229
Role of cytochrome P450 in drug interactions.	2008-10-18	18928560
Drug therapy considerations in arrhythmias in children.	2008-08-01	18679519
The Relationship Between HIV Infection and Cardiovascular Disease.	2008-08	19936197
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.	1991-08	1906902
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.	1991-03-21	1900101
Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.	1991-02-01	1898629
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.	1991-02	1899432
Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide.	1991-01-15	1898998
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.	1991-01	1898640
Combined application of class I antiarrhythmic drugs causes "additive", "reductive", or "synergistic" sodium channel block in cardiac muscles.	1990-11	2176934
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.	1990-09-15	1975861
Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs.	1990-08-01	2114784
Dangerous recurrence of arrhythmia following withdrawal of flecainide.	1990-08	2118487
Amiodarone toxicity: myopathy and neuropathy.	1990-05	2158741
[Effects of oral flecainide treatment of refractory tachyarrhythmias].	1990-05	2115193
Serious interactions of sotalol with amiodarone and flecainide.	1990-03-05	2123962
Profound exacerbation of neuromuscular weakness by flecainide.	1990-02	2105626
Acute urinary retention associated with flecainide.	1990-01-01	2106405
Torsades de pointe with flecainide-amiodarone therapy.	1990	2120306
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.	1989-12	2513143
Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.	1989-12	2480856
[Bidirectional tachycardia during therapy with lorajmine].	1989-10	2605577
Generalized seizures as the presentation of flecainide toxicity.	1989-10	2513205
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium].	1989-09	2510412
Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.	1989-07-15	2500880
Cardioprotective effects of various class I antiarrhythmic drugs in canine hearts.	1989-07	2738264
Rapid suppression of flecainide-induced incessant ventricular tachycardia with high-dose intravenous amiodarone.	1988-04	3127126
[Central nervous system side effects due to anti-arrhythmia therapy. Psychotic depression due to flecainide].	1988-03-11	3127189
Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine.	1987-09	3113836
Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.	1987-08	3117552
[Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients].	1987-06	3115131
[Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril].	1987-03	3034817
Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.	1986-12	3105568
Dysarthria and visual hallucinations due to flecainide toxicity.	1986-01	3099275

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Ventricular Tachycardia Initial dose: 100 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved. Most patients with SUSTAINED VT do not require more than 150 mg every 12 hours (300 mg/day), and the maximum dose recommended is 400 mg/day. Usual Adult Dose for Atrial Fibrillation Initial dose: 50 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved.

Route of Administration: Oral

In Vitro Use Guide

Flecainide produced a dose-dependent prolongation of the cardiac action potential at 1 and 3uM in human pluripotent stem cell-derived cardiomyocytes.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:30:17 GMT 2025` Edited by `admin` on `Wed Apr 02 09:30:17 GMT 2025`
Record UNII	K94FTS1806
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-719273

Preferred Name

English

FLECAINIDE

Official Name

English

N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE

Systematic Name

English

FLECAINIDE [VANDF]

Common Name

English

THN102 COMPONENT FLECAINIDE

Common Name

English

THN-102 COMPONENT FLECAINIDE

Code

English

Flecainide [WHO-DD]

Common Name

English

FLECAINIDE [MI]

Common Name

English

flecainide [INN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175426